5,477
edits
Dual GIP and GLP-1 receptor agonist: Difference between revisions
no edit summary
(Created page with "{{Short description|Dual GIP and GLP-1 receptor agonists, tirzepatide, Mounjaro, Zepbound, retatrutide, multi-receptor incretin therapy, weight loss, diabetes, and W8MD medical weight loss care}} {{DISPLAYTITLE:Dual GIP and GLP-1 Receptor Agonist}} __NOTOC__ {{Infobox drug class | class = Dual GIP and GLP-1 receptor agonist | image = 250px | caption = Dual GIP and GLP-1 receptor agonists act on two incretin pathways involved in...") |
No edit summary |
||
| Line 72: | Line 72: | ||
[[File:Woman-losing-weight.jpeg|thumb|right|350px|Dual GIP and GLP-1 therapy may improve appetite control, blood sugar, and weight loss, but best results require nutrition, activity, sleep, side-effect management, and medical follow-up.]] | [[File:Woman-losing-weight.jpeg|thumb|right|350px|Dual GIP and GLP-1 therapy may improve appetite control, blood sugar, and weight loss, but best results require nutrition, activity, sleep, side-effect management, and medical follow-up.]] | ||
[[File:Before-and-after-weight-loss.jpeg|thumb|right|350px|Before-and-after weight loss image. Individual results with tirzepatide or other incretin therapies vary and require medical supervision.]] | [[File:Before-and-after-weight-loss.jpeg|thumb|right|350px|Before-and-after weight loss image. Individual results with tirzepatide or other incretin therapies vary and require medical supervision.]] | ||
[[File:Sleep-150.png|thumb|left|220px|[[Sleep apnea]] can worsen hunger, fatigue, insulin resistance, cardiovascular risk, and weight regain. W8MD can arrange convenient [[home sleep study]] testing when appropriate.]] | |||
[[File:Sleep-150.png|thumb| | |||
==Overview== | ==Overview== | ||